Compositions for treatment with glucagon-like peptide, and methods of making and using the same

• US 7,589,169 B2
• Filed: 11/03/2005
• Issued: 09/15/2009
• Est. Priority Date: 02/27/2002
• Status: Expired due to Term

• Current Assignee: Pharmain Corporation
• Original Assignee: Pharmain Corporation
• Inventors: Bolotin, Elijah M.
• Primary Examiner(s): Tsang; Cecilia
• Assistant Examiner(s): HEARD, THOMAS SWEENEY
• Application Number:
  US11/266,002
• Publication Number:
  US 20060093660A1
• Time in Patent Office: 1,412 Days
• Field of Search: None
• US Class Current: 530/308
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

Claims

1. A composition with a metal ion bridge comprising:

a linear polyamino acid comprising amino acid monomeric units, selected from the group consisting of poly-lysine, poly-alpha,beta-(2-aminoethyl)-D,L-aspartamide, poly-aspartic acid and poly-glutamic acid, wherein the polyamino acid has a molecular mass ranging from about 1000 to 200,000 daltons;

a chelating group covalently bonded to a monomeric unit;

a transition metal ion coordinately bonded with at least two coordinate bonds to the chelating group and

glucagon like peptide (GLP) coordinately bonded to the transition metal ion, wherein after administration of the composition to a patient, GLP is released from the composition.

2. The composition of claim 1, wherein the polyamino acid is poly-lysine.

3. The composition of claim 1, wherein the polyamino acid further comprises a protective side chain.

4. The composition of claim 3, wherein the protective side chain comprises poly(ethylene glycol).

5. The composition of claim 3, wherein the protective side chain comprises alkoxy poly(ethyleneglycol).

6. The composition of claim 3, wherein the protective side chain comprises methoxy poly(ethyleneglycol) (MPEG).

7. The composition of claim 1, wherein the chelating group comprises a nitrogen containing poly carboxylic acid.

8. The composition of claim 1,

wherein the chelating group comprises one or more of the following:

N-(hydroxy-ethyl)ethylenediaminetriacetic acid;

nitrilotriacetic acid (NIA);

ethylene-bis(oxyethylene-nitrilo)tetraacetic acid;

1,4,7,10-tetraazacyclodo-decane-N,N′

,N″

,N′

″

-tetraacetic acid;

1,4,7,10-tetraaza-cyclododecane-N,N′

,N″

-triacetic acid;

1,4,7-tris(carboxymethyl)-10-(2′

-hydroxypropyl)- 1,4,7,10-tetraazocyclodecane;

1,4,7-triazacyclonane-N,N′

,N″

-triacetic acid;

1,4,8,11 -tetraazacyclotetra-decane-N,N′

,N″

,N′

″

-tetraacetic acid;

diethylenetriamine-pentaacetic acid (DTPA);

ethylenedicysteine;

bis(aminoethanethiol)carboxylic acid;

triethylenetetraamine-hexaacetic acid;

ethylenediamine-tetraacetic acid (EDTA);

or

1,2-diaminocyclohexane-N,N,N′

,N′

-tetraacetic acid.

9. The composition of claim 1, wherein the metal ion is one or more of the following:

Zn²⁺, Ni²⁺, Co²⁺,Fe²⁺,Mn²⁺,or Cu²⁺.

10. The composition of claim 1, wherein the metal ion is Zn²⁺ or Ni²⁺.

11. The composition of claim 3, wherein the polyamino acid is poly-lysine, the protective side chain comprises MPEG, the chelating group comprises NTA, and the metal ion is Zn²⁺.

12. The composition of claim 3, wherein the polyamino acid is poly-lysine, the protective side chain comprises MPEG, the chelating group comprises DTPA, and the metal ion is Zn²⁺.

13. A pharmaceutical composition comprising the composition of claim 3 and a pharmaceutically acceptable diluent or excipient.

14. The pharmaceutical composition of claim 13 wherein the pharmaceutical composition is an injectable composition.

15. The pharmaceutical composition of claim 13, wherein the polyamino acid is poly-lysine, the chelating group comprises NTA, the transition metal ion is Zn²⁺ or Ni²⁺ the protective side chain comprises MPEG, and GLP is GLP- 1.

16. The composition of claim 1, wherein the GLP is GLP-1.

17. The composition of claim 3, wherein the GLP is GLP-1.

18. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable diluent or excipient.

19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is an injectable composition.

20. The composition of claim 1, wherein the polyamino acid is poly-alpha,beta-(2-aminoethyl)-D,L-aspartamide.

21. The composition of claim 1, wherein the polyamino acid is poly-glutamic acid.

22. The composition of claim 1, wherein the polyamino acid is poly-aspartic acid.